The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
CAUSES OF UNSUCCESSFUL RANIBIZUMAB TREATMENT IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN CLINICAL SETTINGS
Abstract
In Brief Purpose: To identify the causes of loss of vision after ranibizumab therapy in patients with exudative age-related macular degeneration treated in three clinical settings. Methods: A retrospective multicentric analysis of 290 consecutive eyes comprising cohorts from 3 clinical settings showed that 21 eyes lost ≥15 letters on the Early Treatment Diabetic Retinopathy Study chart 1 year after the start of ranibizumab treatment. Fundus images of these eyes were analyzed by two independent readers to investigate the causes of visual loss. The three cohorts were compared. A search was made for factors predisposing to visual loss. A second analysis was performed to compare the baseline characteristics of patients who gained (visual acuity gainers) or lost (visual acuity losers) ≥15 letters. Results: Among the 290 eyes included, the proportions from each center experiencing visual loss were not significantly different (mean, 7.24%, P = 0.2631). Mean visual loss of affected eyes was 27 letters. There was no significant difference between these eyes and others as regards age and gender of patients, laterality, type of choroidal neovascularization, number of visits, or initial visual acuity. Visual loss was secondary to the progression of atrophy in eight eyes, fibrosis in five eyes, a combination of fibrosis and atrophy in three eyes, severe subretinal hemorrhage in three eyes, and retinal pigment epithelial tear in two eyes. A significant difference between visual acuity gainers and losers was observed for 2 parameters: age of patients, 80.9 ± 5.3 years in visual acuity losers versus 77.5 ± 7.3 years in visual acuity gainers (P = 0.0473) and visual acuity at diagnosis, respectively, 56.2 ± 11.2 versus 49.0 ± 12.0 (P = 0.0288). Conclusion: Although uncommon, visual loss may occur during ranibizumab treatment and is because of the natural course of age-related macular degeneration in most cases. A multicentric, retrospective study of 290 consecutive eyes treated by ranibizumab showed that at 1 year, 21 eyes (7.2%) lost ≥15 on the Early Treatment Diabetic Retinopathy Study chart. Visual loss was secondary to trophy (eight eyes), fibrosis (five eyes), fibrosis and atrophy (three eyes), subretinal hemorrhage (three eyes), and retinal pigment epithelial tear (two eyes).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“scar formation has been identified as one of the causes of visual acuity loss after treatment.9”
From Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials (2014) · cites this paper as [9]
In the citing paper
“Scar and atrophy are the two most important morphological features that influence visual outcomes in untreated nAMD as well as in patients treated with anti-VEGF intravitreal injections.6,7”
From Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials (2018) · cites this paper as [6]
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 2×
“2 letters.(3) In both trials, monthly injections of ranibizumab allowed severe loss of visual acuity to be avoided in most of the treated eyes.”
BackgroundResultFung, A. E., Lalwani, G. A., Rosenfeld, P. J., Dubovy, S. R., Michels, S., Feuer, W. J., Puliafito, C. A., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.028 · Cited by 972 · cited 3×
“Its protocol comprised three initial monthly injections of ranibizumab, followed by a pro re nata decision to retreat or not to re-treat, based on the evolution of visual acuity and the presence or absence of subfoveal fluid, as observed by OCT.(34) In the 2-year report of the results, no patient who completed the fol…”
MethodInfluentialLalwani, G. A., Rosenfeld, P. J., Fung, A. E., Dubovy, S. R., Michels, S., Feuer, W., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.01.024 · Cited by 880 · cited 1×
“15 letters.(35) The PrONTO investigation was a prospective study that included 40 patients.”
BackgroundRegillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration
Wong, T., Chakravarthy, U., Klein, R., Mitchell, P., Zlateva, G., Buggage, R., Fahrbach, K., Probst, C., & Sledge, I. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.008 · Cited by 601 · cited 5×
“Fourteen eyes presented with subfoveal classic CNV, and 86 eyes presented with occult CNV.”
BackgroundInfluentialRosenfeld, P. J., Shapiro, H., Tuomi, L., Webster, M., Elledge, J., & Blodi, B. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.07.011 · Cited by 252
Ultrastructural Findings in the Primate Eye After Intravitreal Injection of Bevacizumab
Peters, S., Heiduschka, P., Julien, S., Ziemssen, F., Fietz, H., Bartz-Schmidt, K. U., & Schraermeyer, U. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.03.007 · Cited by 229 · cited 1×
“Two experimental studies have shown that bevacizumab, injected into the vitreous of rats and primates, reduces the fenestrations in the choriocapillaris.(31,32) Thus, there is a theoretical concern that repeated injections of bevacizumab may induce significant changes in the choriocapillaris and accelerate geographic…”
BackgroundComplications in patients after intravitreal injection of bevacizumab
Shima, C., Sakaguchi, H., Gomi, F., Kamei, M., Ikuno, Y., Oshima, Y., Sawa, M., Tsujikawa, M., Kusaka, S., & Tano, Y. (2008) · Acta Ophthalmologica · doi:10.1111/j.1600-0420.2007.01067.x · Cited by 200 · cited 1×
“9%.(13,17,19,29,30) The previously identified risk factors for RPE tears are advanced age and the presence of fibrovascular RPE detachment.”
BackgroundPathophysiology and management of subretinal hemorrhage
Hochman, M. A., Seery, C. M., & Zarbin, M. A. (1997) · Survey of Ophthalmology · doi:10.1016/s0039-6257(97)00089-1 · Cited by 186
Cited by
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335
“treatment generally stabilizes or improves visual acuity, scar formation has been identified as one of the causes of visual acuity loss after treatment.(9) The factors associated with scarring after anti-VEGF therapy have not been described.”
Khanani, A. M., Kotecha, A., Chang, A., Chen, S.-J., Chen, Y., Guymer, R., Heier, J. S., Holz, F. G., Iida, T., Ives, J. A., et al. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.02.014 · Cited by 227
Self-citationMolecular mechanisms of subretinal fibrosis in age-related macular degeneration
Ishikawa, K., Kannan, R., & Hinton, D. R. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2015.03.009 · Cited by 236
“…therapy has become a standard treatment that improves visual acuity or at least prevents severe vision loss in nAMD patients with CNV, some patients have a poor response to the therapy, resulting in visual impairment despite frequent intravitreal injections of the drugs (Cohen et al., 2012).”
Krebs, I., Glittenberg, C. G., Ansari‐Shahrezaei, S., Hagen, S., Steiner, I., & Binder, S. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303513 · Cited by 126
Daniel, E., Pan, W., Ying, G.-S., Kim, B. J., Grunwald, J. E., Ferris, F. L., Jaffe, G. J., Toth, C. A., Martin, D. F., Fine, S. L., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.01.004 · Cited by 119
“Scar and atrophy are the 2 most important morphologic features that influence visual outcomes in untreated nAMD, as well as in patients treated with anti-VEGF intravitreal injections.(6,7) Scars thicker than 0.”
Background
Metadata
- Authors
- Cohen, S. Y., Oubraham, H., Uzzan, J., Dubois, L., & Tadayoni, R.
- Affiliations
- Hôpital Lariboisière (FR)
- Corresponding author
- Cohen, Salomon Y.
- Dubois, Lise
- Venue
- Retina
- Published
- 2012-09
- Volume
- 32
- Issue
- 8
- Pages
- 1480-1485
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2086688665
- Cited by
- 61
- References
- 35
- Citations by year
- 2025: 10 · 2024: 8 · 2023: 6 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 4 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 1
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, neovascular age-related macular degeneration, choroidal neovascularization, visual acuity loss, macular atrophy, subretinal fibrosis, subretinal hemorrhage, retinal pigment epithelial tear, patient age, natural disease course, retinal imaging
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Atrophy, Exudates and Transudates, Female, Fibrosis, Humans, Male, Middle Aged, Retina, Retrospective Studies, Risk Factors, Vision Disorders, Visual Acuity, Treatment Failure, Angiogenesis Inhibitors, Tomography, Optical Coherence, Wet Macular Degeneration, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CAUSES OF UNSUCCESSFUL RANIBIZUMAB TREATMENT IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN CLINICAL SETTINGS. https://app.cochat.ai/papers/10.1097/iae.0b013e318240a516
- The paper
- Cohen, S. Y., Oubraham, H., Uzzan, J., Dubois, L., & Tadayoni, R. (2012). CAUSES OF UNSUCCESSFUL RANIBIZUMAB TREATMENT IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN CLINICAL SETTINGS. Retina. https://doi.org/10.1097/iae.0b013e318240a516
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.